Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TG Therapeutics, Inc. - Common Stock
(NQ:
TGTX
)
61.42
+1.47 (+2.45%)
Delayed Quote
Updated: 11:20 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TG Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
10 Biggest Price Target Changes For Monday
↗
April 18, 2022
Raymond James cut The Estée Lauder Companies Inc. (NYSE: EL) price target from $390 to $345. Estée Lauder shares rose 0.4% to $264.95 in pre-market trading.
Via
Benzinga
21 Stocks Moving in Monday's Pre-Market Session
↗
April 18, 2022
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack...
Via
Benzinga
TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood Cancers
↗
April 18, 2022
Via
Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
↗
April 17, 2022
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...
Via
Benzinga
TG Therapeutics: Q4 Earnings Insights
↗
March 01, 2022
TG Therapeutics (NASDAQ:TGTX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For March 1, 2022
↗
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold On Blood Cancer Trials
↗
January 27, 2022
TG Therapeutics Inc's (NASDAQ: TGTX) CEO Michael Weiss said that the FDA has
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
April 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
↗
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
TG Therapeutics, Inc. (NASDAQ:TGTX) Investor Alert: Investigation over Potential Wrongdoing
↗
March 23, 2022
San Diego, CA -- (SBWIRE) -- 03/23/2022 -- Certain directors of TG Therapeutics, Inc are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Looking Into TG Therapeutics's Return On Capital Employed
↗
March 04, 2022
TG Therapeutics (NASDAQ:TGTX) brought in sales totaling $2.32 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.99%, resulting in a loss...
Via
Benzinga
Where TG Therapeutics Stands With Analysts
↗
January 24, 2022
Within the last quarter, TG Therapeutics (NASDAQ:TGTX) has observed the fol...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings
↗
March 03, 2022
The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ: TGTX) biologics license application and supplemental New Drug Application for...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
↗
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
February 03, 2022
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...
Via
FinancialNewsMedia
Massive Month-End Buying of Biggest Losers
↗
January 31, 2022
The average stock in the Russell 3,000 is now up 7% from the index’s low point last Friday as we near the final close of January 2022.
Via
Talk Markets
52 Biggest Movers From Friday
↗
January 31, 2022
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
64 Biggest Movers From Yesterday
↗
January 28, 2022
Check out these penny stocks insiders are buying Losers ION Geophysical Corporation (NYSE: IO) shares fell 53.6% to settle at $0.51 on Thursday. Epizyme, Inc. (NASDAQ:...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
January 27, 2022
Gainers Galapagos (NASDAQ:GLPG) stock rose 21.4% to $64.75 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.5 million, which is...
Via
Benzinga
46 Stocks Moving In Thursday's Mid-Day Session
↗
January 27, 2022
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 158.2% to $7.23 after tumbling 18% on Wednesday. Indonesia Energy said it projects to commence drilling...
Via
Benzinga
10 Biggest Price Target Changes For Monday
↗
January 24, 2022
SVB Leerink cut Biogen Inc. (NASDAQ:BIIB) price ...
Via
Benzinga
TG Therapeutics, Inc. (NASDAQ:TGTX) Investor Notice: Investigation over Possible Violations of Securities Laws
↗
January 20, 2022
San Diego, CA -- (SBWIRE) -- 01/20/2022 -- TG Therapeutics, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
NASDAQ:TGTX Investor Notice: Investigation over Possible Securities Laws Violations by TG Therapeutics, Inc.
↗
January 19, 2022
San Diego, CA -- (SBWIRE) -- 01/19/2022 -- An investigation was announced concerning potential securities laws violations by TG Therapeutics, Inc. in connection with certain financial statements.
Via
SBWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 05, 2022
Gainers SomaLogic (NASDAQ:SLGC) shares mo...
Via
Benzinga
TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TG Therapeutics, Inc. on Behalf of TG Therapeutics Stockholders and Encourages Investors to Contact the Firm
December 03, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
63 Biggest Movers From Friday
↗
December 20, 2021
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
December 01, 2021
Morgan Stanley boosted Zscaler, Inc. (NASDAQ: ZS) price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading. Citigroup boosted Applied...
Via
Benzinga
52 Biggest Movers From Yesterday
↗
December 01, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 30, 2021
Gainers Cumberland (NASDAQ:CPIX) stock...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
